Braveheart Bio raises $383 million in Nasdaq IPO to advance Hengrui cardiovascular drug to Phase 3
read at Endpoints ↗DealPositive
Braveheart Bio, a U.S. biotech spun out of China’s Hengrui Pharmaceuticals, completed an initial public offering on the Nasdaq.
The offering generated about $383 million in gross proceeds, providing capital to move the company’s cardiovascular candidate into a Phase 3 clinical trial.
The funding underscores investor interest in cross‑border biotech collaborations and positions Braveheart to further develop the Hengrui‑origin drug.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3”
read at Endpoints ↗86 words · retrieved 2h ago
comments(0)
5-min edit window · permanent after that